External broker reports(aggregated public sources), Axis Direct

Axis Direct

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<div><div><div><div><ul><li>Lupin is an innovation-led transnational pharmaceutical company.</li><li>It, develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs.</li><li>The cCompany enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. </li></ul></div></div></div></div><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Lupin is an innovation-led transnational pharmaceutical company.It, develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs.The cCompany enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Pick of the Week: Lupin Ltd - 10 JULY 2023

<ul><li>Lupin has received approval from generic version of Spiriva HandiHaler (Tiotropium Bromide Inhalation Powder) from USFDA in the US Market.</li><li>This is the first generic version of Spiriva that provides edge for Lupin to garner higher market share.</li><li>This drug is used in treatment of patients with chronic obstructive pulmonary disease (COPD).</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Lupin has received approval from generic version of Spiriva HandiHaler (Tiotropium Bromide Inhalation Powder) from USFDA in the US Market.This is the first generic version of Spiriva that provides edge for Lupin to garner higher market share.This drug is used in treatment of patients with chronic obstructive pulmonary disease (COPD).Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Lupin - GSpiriva Approval a Overall Turnaround in The Business

Global Healthcare Analyst

Tina Banerjee

Zydus Lifesciences Ltd / Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/zydus-lifesciences-ltd" target="_blank" data-smartkarma-citation="entities:12914:1" rel="noopener">Zydus Lifesciences Ltd (ZYDUSLIF IN)</a> recorded 32% growth in revenue to INR50B in Q4FY23, driven by 58% YoY growth in US formulation business. India business revenue grew 11% YoY.</li>
<li>US business growth was driven by volume expansion in existing products and new launches. The company has launched eight new products in the US during the quarter.</li>
<li>Going ahead, growth is expected to moderate, due to high base effect. The company expects single-digit growth in the US business in FY24, slower than 28% growth recorded in FY23.</li>
</ul>



Zydus Lifesciences Ltd (ZYDUSLIF IN) recorded 32% growth in revenue to INR50B in Q4FY23, driven by 58% YoY growth in US formulation business. India business revenue grew 11% YoY.
US business growth was driven by volume expansion in existing products and new launches. The company has launched eight new products in the US during the quarter.
Going ahead, growth is expected to moderate, due to high base effect. The company expects single-digit growth in the US business in FY24, slower than 28% growth recorded in FY23.


Zydus Lifesciences (ZYDUSLIF IN): Strong Q4 Result Driven by US Business; Forward Growth to Moderate

Dr. Reddy's Laboratories / Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/dr-reddy-s-laboratories-ltd" target="_blank" data-smartkarma-citation="entities:16406:1" rel="noopener">Dr. Reddy's Laboratories (DRRD IN)</a> announced mixed Q4FY23 result, with revenue beating consensus and net profit missing expectations. Both revenue and net profit grew YoY but declined sequentially.</li>
<li>North America grew 27% YoY (but declined 17% QoQ) to INR25.3B, driven by new product launches, growing market share in certain existing products, and favorable Fx movement.</li>
<li>Revenue from India business increased 32% YoY and 14% QoQ to INR12.8B, driven by favorable price variance, new product launches including acquired/in-licensed products, and non-core brand divestments.</li>
</ul>



Dr. Reddy's Laboratories (DRRD IN) announced mixed Q4FY23 result, with revenue beating consensus and net profit missing expectations. Both revenue and net profit grew YoY but declined sequentially.
North America grew 27% YoY (but declined 17% QoQ) to INR25.3B, driven by new product launches, growing market share in certain existing products, and favorable Fx movement.
Revenue from India business increased 32% YoY and 14% QoQ to INR12.8B, driven by favorable price variance, new product launches including acquired/in-licensed products, and non-core brand divestments.


Dr. Reddy's Laboratories (DRRD IN): Q4FY23 Result- Sequential Decline in Key Parameters

<ul><li>Sales were up 14.1% YoY at Rs 4,330 Cr, majorily led by India business (+9.5% YoY), APAC (+15% YoY) and API business (+46% YoY) while US business remains flat at $175 on a QoQ basis.</li><li>US sales got impacted due to the lack of new launches and seasonality, gSupreb has strong volume growth, and Alubetrol has a stable market share of +20%.</li><li>Diabetic business was impacted due to the genericization of patented products while strong growth in Respiratory, Cardiac and Gynaec was seen.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Sales were up 14.1% YoY at Rs 4,330 Cr, majorily led by India business (+9.5% YoY), APAC (+15% YoY) and API business (+46% YoY) while US business remains flat at $175 on a QoQ basis.US sales got impacted due to the lack of new launches and seasonality, gSupreb has strong volume growth, and Alubetrol has a stable market share of +20%.Diabetic business was impacted due to the genericization of patented products while strong growth in Respiratory, Cardiac and Gynaec was seen.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

LUPIN Ltd - Margins Improvement to Be The Key to Future Performance

India

Lupin Limited manufactures bulk actives and formulations. The principal bulk actives manufactured by it include Rifampicin, Pyrazinamide, Ethambutol (anti-TB), Cephalosporins (anti-infectives) and cardiovasculars. The company also possesses competencies in phytomedicines, in which medicines are made out of plant and herbal resources supported by the discipline of modern medicine.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Lupin Ltd (LPC IN)

Pick of the Week: Lupin Ltd - 10 JULY 2023

Lupin is an innovation-led transnational pharmaceutical company. It, develops and commercializes a wide range of branded and generic formulations,...

Axis Direct

Lupin - GSpiriva Approval a Overall Turnaround in The Business

Lupin has received approval from generic version of Spiriva HandiHaler (Tiotropium Bromide Inhalation Powder) from USFDA in the US Market.

Axis Direct

Zydus Lifesciences (ZYDUSLIF IN): Strong Q4 Result Driven by US Business; Forward Growth to Moderate

Zydus Lifesciences recorded 32% revenue growth to INR50B in Q4FY23, driven by 58% growth in US formulation business. The company expects single...

Tina Banerjee

Dr. Reddy's Laboratories (DRRD IN): Q4FY23 Result- Sequential Decline in Key Parameters

Dr. Reddy's announced mixed Q4 result, with revenue beating consensus and net profit missing expectations. Both revenue and net profit grew YoY but...

Tina Banerjee

LUPIN Ltd - Margins Improvement to Be The Key to Future Performance

US sales got impacted due to the lack of new launches and seasonality, gSupreb has strong volume growth, and Alubetrol has a stable market share of...

Axis Direct

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)